System and method for early detection of alzheimers by detecting amyloid-beta using orbital angular momentum

• US 9,784,724 B2
• Filed: 10/05/2015
• Issued: 10/10/2017
• Est. Priority Date: 07/24/2014
• Status: Active Grant

• Current Assignee: Nxgen Partners Ip, LLC (NxGen Partners LLC)
• Original Assignee: Nxgen Partners Ip, LLC (NxGen Partners LLC)
• Inventors: Ashrafi, Solyman, Linquist, Roger
• Primary Examiner(s): Stafira, Michael P
• Application Number:
  US14/875,507
• Publication Number:
  US 20160097774A1
• Time in Patent Office: 736 Days
• CPC Class Codes: G01N 2333/4709 Amyloid plaque core protein
• CPC Class Codes: G01N 2800/2821 Alzheimer
• CPC Class Codes: G01N 33/487 of liquid biological material
• CPC Class Codes: G01N 33/6896 Neurological disorders, e.g. Alzheimer's disease

Abstract

An apparatus for measuring a concentration of amyloid-beta within a sample includes signal generation circuitry and a detector. The signal generation circuitry generates a first signal having an applied first orbital angular momentum signature and applies the first signal to the sample. The detector receives the first signal after it passes through the sample and determines the concentration of the amyloid-beta within the sample based on a detected second orbital angular momentum signature within the first signal received from the sample. The detector provides an output of the determined concentration as an indication for determining an early onset of Alzheimer'"'"'s.

Claims

1. An apparatus for measuring a concentration of amyloid-beta within a sample, comprising:

signal generation circuitry for generating a first signal having an applied first orbital angular momentum signature and applying the first signal to the sample; and

a detector for receiving the first signal after it passes through the sample and determining the concentration of the amyloid-beta within the sample based on a detected second orbital angular momentum signature within the first signal received from the sample, the detector providing an output of the determined concentration to provide an indication of early onset Alzheimer'"'"'s.

2. The apparatus of claim 1, wherein the second orbital angular momentum signature further comprises a change in an eccentricity of a mode intensity, a shift in a center of gravity of the mode intensity and a rotation of the ellipsoidal intensity output of the mode intensity.

3. The apparatus of claim 2, wherein the detector negates effects of at least one of sample distribution due to gravity, angle of camera recording the mode intensity to the sample, a container holding the sample, an angle of incidence of the first beam to the sample and an angle exit of the first beam from the sample to detect the change in the eccentricity of the mode intensity.

4. The apparatus of claim 1, wherein the second orbital angular momentum signature comprise topological features of the first light beam after passing through the sample.

5. The apparatus of claim 1, wherein the sample is located in the eye of a patient.

6. The apparatus of claim 1, wherein the signal generation circuitry further comprises:

an emitting source for emitting the first signal comprising a plurality of plane waves; and

orbital angular momentum generation circuitry for receiving the first signal and applying the orbital angular momentum signature to the first signal to provide an orbital angular momentum twisted signal.

7. The apparatus of claim 1, wherein the detector further includes circuitry for determining a phase of the first signal after it passes through the sample, wherein the circuitry determines the phase by interfering the first signal having the second orbital angular momentum signature therein with the first signal having the plane waves therein.

8. The apparatus of claim 1, wherein the signal generation circuitry further comprises a hologram implemented with at least one of an amplitude mask, a phase mask, a spatial light modulator and a digital light processor.

9. The apparatus of claim 1, wherein the detector further comprises:

an orbital angular momentum detector for determining the detected signature of the orbital angular momentum within the first signal from the sample; and

a processor for determining a concentration of the amyloid-beta within the sample responsive to the detected second orbital angular momentum signature.

10. The apparatus of claim 1, wherein differing signatures indicate different concentrations of the amyloid-beta within the sample.

11. An apparatus for measuring a concentration of amyloid-beta within a sample, comprising:

an emitting source for emitting a light beam comprising a plurality of plane waves;

orbital angular momentum generation circuitry for receiving the light beam, applying an orbital angular momentum signature to the first signal to provide an orbital angular momentum twisted signal that is applied to the sample; and

a detector for receiving the first signal after it passes through the sample and determining the concentration of the amyloid-beta within the sample based on a detected second orbital angular momentum signature within the first signal received from the sample, wherein the second orbital angular momentum signature further comprises a change in an eccentricity of a mode intensity, a shift in a center of gravity of the mode intensity and a rotation of the ellipsoidal intensity output of the mode intensity, further wherein differing signatures indicate different concentrations of the amyloid-beta within the sample.

12. The apparatus of claim 11, wherein the detector negates effects of at least one of sample distribution due to gravity, angle of camera recording the mode intensity to the sample, a container holding the sample, an angle of incidence of the first beam to the sample and an angle exit of the first beam from the sample to detect the change in the eccentricity of the mode intensity.

13. The apparatus of claim 11, wherein the second orbital angular momentum signature comprise topological features of the first light beam after passing through the sample.

14. The apparatus of claim 11, wherein the detector further determines whether the concentration of amyloid-beta provides an indication of Alzheimer'"'"'s.

15. The apparatus of claim 11, wherein the sample is located in the eye of a patient.

16. The apparatus of claim 12, wherein the signal generation circuitry further comprises a hologram implemented with at least one of an amplitude mask, a phase mask, a spatial light modulator and a digital light processor.

17. The apparatus of claim 11, wherein the detector further comprises:

an orbital angular momentum detector for determining the detected second signature of the orbital angular momentum within the first signal from the sample; and

a processor for determining a concentration of the amyloid-beta within the sample responsive to the detected second orbital angular momentum signature.

18. The apparatus of claim 11, wherein the detector further includes circuitry for determining a phase of the first signal after it passes through the sample, wherein the circuitry determines the phase by interfering the first signal having the second orbital angular momentum signature therein with the first signal having the plane waves therein.

19. A method for detecting and early onset of Alzheimer'"'"'s based upon amyloid-beta concentration, comprising:

generating a first signal having an orbital angular momentum signature applied thereto;

applying the first signal to the sample;

receiving the first signal after it passes through the sample;

detecting a second orbital angular momentum signature within the received first signal;

determining the concentration of amyloid-beta within the sample based on a detected second orbital angular momentum signature within the first signal received from the sample; and

determining if the concentration of amyloid-beta provides an indication of an early onset of Alzheimer'"'"'s.

20. The method of claim 19, wherein detecting further comprises detecting a change in an eccentricity of mode intensity, a shift in a center of gravity of the mode intensity and a rotation of the ellipsoidal intensity output of the mode intensity.

21. The method of claim 20, wherein detecting further comprises negating effects of at least one of sample distribution due to gravity, angle of camera recording the mode intensity to the sample, a container holding the sample, an angle of incidence of the first beam to the sample and an angle exit of the first beam from the sample to detect the change in the eccentricity of the mode intensity.

22. The method of claim 19, wherein detecting further comprises detecting a topological features of a mode intensity of the first signal after passing the first signal through the sample.

23. The method of claim 19, wherein the step of applying further comprises the step of applying the first signal to an eye of a patient in a non-intrusive manner.

24. The method of claim 19, wherein the step of generating further comprises:

emitting the first signal comprising a plurality of plane waves from a laser;

receiving the first signal; and

applying the orbital angular momentum signature to the first signal to provide an orbital angular momentum twisted signal.

25. The method of claim 19, wherein the step of determining a concentration further comprises determining a phase of the first signal after it passes through the sample.

26. The method of claim 25, wherein the step of determining the phase further comprises interfering the first signal having the second orbital angular momentum signature therein with the first signal having the plane waves therein.

27. The method of claim 19, wherein the step of generating the first signal further comprises generating the first signal using a hologram implemented with at least one of an amplitude mask, a phase mask, a spatial light modulator and a digital light processor.

28. The method of claim 19, wherein differing signatures indicate different concentrations of the amyloid-beta within the sample.

29. The method of claim 19 further including:

receiving the first signal after the first signal passes through the sample; and

amplifying a first portion of the signal having the detected value of the orbital angular momentum associated therewith.

30. A method for detecting and early onset of Alzheimer'"'"'s based upon amyloid-beta concentration, comprising:

performing an alkaline pretreatment on an amyloid-beta sample, the step of performing comprising;

placing a predetermined amount of the amyloid-beta sample in a first micro-centrifuge tube;

dissolving the predetermined amount of the amyloid-beta sample in NaOH;

sitting the dissolved amyloid-beta sample for a first predetermined period of time;

sonicating the dissolved amyloid-beta sample for a second predetermined period of time;

piercing the first micro-centrifuge tube;

placing the first micro-centrifuge tube in liquid nitrogen;

lyophilizing the amyloid-beta sample for a third predetermined period of time;

preparing filters for filtering the lyophilized amyloid-beta sample, the step of preparing comprising;

washing two centrifugal filters with a phosphate buffer;

placing each of the two centrifugal filters inside a micro-centrifuge tube;

filtering the lyophilized amyloid-beta sample with the filters, the step of filtering comprising;

dissolving the lyophilized amyloid-beta sample in distilled water;

placing the dissolved, lyophilized amyloid-beta sample in the micro-centrifuge tubes;

sonicating the dissolved, lyophilized amyloid-beta sample for a fourth predetermined period of time;

centrifuging the sonicated amyloid-beta sample for a fifth predetermined period of time to provide amyloid-beta test sample;

generating a first signal having an orbital angular momentum signature applied thereto;

applying the first signal to the amyloid-beta test sample;

receiving the first signal after it passes through the amyloid-beta test sample;

detecting a second orbital angular momentum signature within the received first signal;

determining the concentration of amyloid-beta within the amyloid-beta test sample based on a detected second orbital angular momentum signature within the first signal received from the amyloid-beta test sample; and

determining if the concentration of amyloid-beta provides an indication of an early onset of Alzheimer'"'"'s.